Clinical Trial Search Results
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)
This study is currently enrolling.
Madrigal Pharmaceuticals, Inc. has begun a study of an investigational product (also known as the “study drug”) called resmetirom as a possible treatment for NASH cirrhosis. An investigational drug is one that has not been appr ...
A Randomized Phase 3 Study Assessing the Efficacy and Safety
of Olvi-Vec followed by Platinum-doublet Chemotherapy and
Bevacizumab Compared with Platinum-doublet Chemotherapy and
Bevacizumab in Women with Platinum-Resistant/Refractory
Ovarian Cancer (OnPrime Study
of Olvi-Vec followed by Platinum-doublet Chemotherapy and
Bevacizumab Compared with Platinum-doublet Chemotherapy and
Bevacizumab in Women with Platinum-Resistant/Refractory
Ovarian Cancer (OnPrime Study
This study is currently enrolling.
You are invited to take part in a research study. This research study is studying Olvi-Vec as a possible treatment for platinum-resistant or platinum-refractory ovarian cancer including fallopian tube cancer and peritoneal carc ...
A Randomized PHase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
This study is currently enrolling.
This is a study involving an investigational (experimental) drug called MRTX849, being developed by Mirati Therapeutics, Inc., which is the company that provides MRTX849 study drug and is funding and organizing the study. Inves ...
A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
This study is currently enrolling.
This study is being done to answer the following question: Will adding an immune checkpoint inhibitor to the usual combination of chemotherapy drugs help prevent your cancer from getting worse? We are doing this study because w ...
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
This study is currently enrolling.
The main purpose of the study is to find out if patients treated with remibrutinib may experience fewer MS relapses (also called clinical attacks, exacerbations or flare ups) than patients treated with teriflunomide (also known ...
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)
This study is currently enrolling.
Study CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter taken in ...
A Randomized, Double-blind, Placebo-controlled, 12-month Phase 3 Study to Evaluate the Effect of Venglustat on Neuropathic and Abdominal Pain in Male and Female Adults with Fabry Disease who are Treatment-naïve or Untreated for
At least 6 Months
At least 6 Months
This study is currently enrolling.
The purpose of the study is to evaluate daily oral doses of the study drug called venglustat compared to placebo: what is the effectiveness (how well it works) on symptoms of the Fabry disease, mainly neuropathic pain and abdom ...
A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML) (VIALE-T)
This study is currently enrolling.
The purpose of this study is to evaluate the safety and efficacy of study drugs venetoclax and azacitidine compared to Best Supportive Care (no study medication) when given as maintenance therapy after allogeneic stem cell tran ...
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1
Versus Treatment of Physician’s Choice in Patients With Previously
Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative
Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients
Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose
Tumors Do Express PD-L1
This study is currently enrolling.
This study will be recruiting patients with previously untreated, locally advanced, inoperable or metastatic Triple-Negative Breast Cancer whose tumors do not express PD-L1 or patients previously treated with Anti PD-(L)1 Agent ...